
Item 1 – Cover Page



Eventide Asset Management, LLC

60 State Street, Suite 700, Boston, MA 02109

877-771-3836

www.eventidefunds.com

March 31, 2015

Form ADV Part 2A (Brochure)

This brochure provides information about the qualifications and business practices of Eventide Asset Management, LLC. If you have any questions about the contents of this brochure, please contact us at 877-771-3836, Ext. 108 and/or bjcheria@eventidefunds.com. The information in this brochure has not been approved or verified by the United States Securities and Exchange Commission or by any state securities authority.

Additional information about Eventide Asset Management, LLC also is available on the SEC's website at www.adviserinfo.sec.gov.

Eventide Asset Management, LLC is a registered investment adviser. Registration of an investment adviser does not imply any level of skill or training. The oral and written communications of an adviser provide you with information to help you determine to hire or retain an adviser.

Item 2 – Material Changes

In order to assist clients in reviewing this Brochure, you will find a summary of material changes to our Brochure below. Please note that we are only discussing material changes since our last annual update on March 28, 2014.

Update on Item 4 – Advisory Business

The section has been modified to be more concise and direct , and highlight differences between the mutual funds and model portfolios managed by the Adviser. There has been a substantial change in the Adviser's discretionary assets since our last annual update.

Item 10 – Other Financial Industry Activities and Affiliations

Jason Myhre, the Director of Sales and Marketing for the Adviser, has began the process of becoming a registered and supervised representative of the broker dealer, Northern Lights Distributors, LLC.

Item 12 – Brokerage Practices

The soft dollar benefits paragraph has been modified to highlight how the research the Adviser receives benefits different clients.

Item 17 – Voting Client Securities

The section has been modified to be more concise and direct. Additional information in regards to the Adviser's ability to use a Third Party proxy voting service provider has been added.

Note: We will provide you with a new Brochure as necessary based on changes or new information, at any time, without charge.

Our Brochure may be requested by contacting BJ Cheriakalath, Chief Compliance Officer at 877-771-3836 Ext. 108 or bjcheria@eventidefunds.com.

Item 3 -Table of Contents

Item 2 – Material Changes.....	2
Item 3 -Table of Contents.....	3
Item 4 – Advisory Business.....	4-5
Item 5 –Fees and Compensation.....	5-6
Item 6 – Performance-Based Fees and Side-By-Side Management.....	6
Item 7 – Types of Clients.....	6
Item 8 – Methods of Analysis, Investment Strategies and Risk of Loss.....	6-8
Item 9 – Disciplinary Information.....	8
Item 10 – Other Financial Industry Activities and Affiliations.....	8-9
Item 11 – Code of Ethics.....	9-10
Item 12 – Brokerage Practices	10-12
Item 13 – Review of Accounts	12
Item 14 – Client Referrals and Other Compensation.....	13
Item 15 – Custody.....	13
Item 16 – Investment Discretion.....	13
Item 17 – Voting Client Securities.....	13-14
Item 18 – Financial Information.....	14

Item 4 – Advisory Business

Eventide Asset Management, LLC (the “Adviser”) a Delaware limited liability company, was formed in April of 2008 and registered as an investment adviser with the SEC in June of 2008. The Adviser's ownership structure is composed of both founding members and limited partners. The only principal owner (voting shares greater than or equal to 25%) is Dr. Finny Kuruvilla. Dr. Kuruvilla is the CIO of the Adviser.

Portfolio management of 1940 Act mutual funds is currently the Adviser's primary business. The Adviser makes ongoing investment decisions for the mutual funds, which at the time of this brochure include the Eventide Gilead Fund (“Gilead Fund”) and the Eventide Healthcare & Life Sciences Fund (“HLS Fund”) (together the “Funds”), and directs portfolio transactions on behalf of the Funds. The Adviser also provides portfolio management for model portfolios used in wrap fee programs, which at the time of this brochure include the Eventide Midcap Folio, Eventide Healthcare Folio, and Eventide I&G Model (together the “Models”). The Adviser is not responsible for directing portfolio transactions on behalf of the Models.

The Adviser tailors its Advisory services to the individual needs of clients, granted that the Adviser will not enter into an advisory agreement that is inconsistent with the values of the Adviser. The Adviser analyzes potential investments not only for financial strengths and outlook, but also for the company's ability to operate with integrity and create value for customers, employees, supply chain, host communities, environment, and society. While few companies may reach these ideals in every area of their business, these principles articulate the Adviser's highest expectations for corporate behavior, and directly impacts the Adviser's portfolio management process. The Adviser manages the investment of the assets of each Fund in conformity with the investment objectives and policies of the Fund, which includes restrictions or limitations imposed by the Fund on investing in certain securities or types of securities, as well as requirements to invest a minimum level of assets in certain securities or types of securities. The Adviser is responsible for creating an accurate and complete description of the investment style and/or objectives of each Model, and managing the Models in accordance with the descriptions.

The Funds, based on its investment objectives, may invest a portion of the portfolio into options, short positions, and private companies. The recommendations made by the Adviser to the Model portfolios, on the other hand, are long equity only. Unlike the Funds, the Adviser does not have discretionary authority over the Models used in the wrap fee programs. Accordingly, the Adviser does not control trade execution in the programs, but generally expects there to be a delay between Model changes and any resulting trades. If Eventide causes a Fund to buy or sell a security and also changes the allocation of the same security in a wrap fee program's Model portfolio, Eventide will first initiate the trades for the Fund and then update the wrap fee program's Model portfolio. This may lead to less favorable execution for the Models. The sponsors in the wrap fee programs maintain discretionary authority over their clients' accounts and can choose to accept or reject all or any portion of the Model portfolios that the Adviser provides. The program sponsors also determine allocation percentages, and are under no obligation to continue to use the

portfolios within their programs. As described in more detail under the Fees and Compensation Section below, the Adviser receives a portion of the wrap fee for the services the Adviser provides to the Models.

As of March 23, 2015, the Adviser managed \$1,699,570,929 in assets on a discretionary basis between the Funds, and \$15,316,532 on a non-discretionary basis across the Models.

Item 5 – Fees and Compensation

The Adviser is paid a monthly management fee at the annual rate of 1.00% of the average daily net assets for the Gilead Fund and 1.10% of the average daily net assets for the Healthcare and Life Sciences Fund. The Board of Trustees for the Funds reviews management fees with the Adviser as part of the 15(c) process. The Adviser has contractually agreed to waive fees and/or reimburse expenses but only to the extent necessary to maintain the Fund's total annual operating expenses at 1.42% for all share classes of the Gilead Fund and 1.43% for all share classes of the Healthcare and Life Sciences Fund through October 31, 2015. The fee waiver and expense reimbursements excludes front-end or contingent deferred loads, any Rule 12b-1 fees, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expense on securities sold short, underlying fund fees, other expenses (such as fees charged by the Fund's service providers and Fund's custodian) or extraordinary expenses such as litigation, which are all paid by the Fund. Each waiver or reimbursement by the Adviser is subject to repayment by the Fund within the three fiscal years following the fiscal year in which that particular expense is incurred, if the Fund is able to make the repayment without exceeding any expense limitation in effect at the time of the waiver and the repayment is approved by the Board of Trustees. The Funds' Administrator deducts the management fees from Fund assets and pays the Adviser on a monthly basis.

The Adviser pays expenses incurred by it in connection with acting as Adviser to the Funds, other than costs of securities purchased for the Funds and other expenses paid by the Funds as detailed in the Investment Advisory Agreement. Costs of securities purchased for the Funds includes taxes and brokerage commissions, borrowing costs, costs of investing in underlying funds and extraordinary expenses, if any. *For more information on Eventide's Brokerage Practices, please see Item 12.*

The Adviser receives asset-based fees for the Models, which are negotiated with the wrap fee program sponsor. The wrap fee program sponsors generally pays 30-60 basis points annually to the Adviser on its monthly assets depending on account types. Management fees are calculated and deducted from the wrap fee sponsor's client accounts by the

program's custodian and paid to the Adviser monthly or quarterly. The Adviser's fees exclude possible brokerage commissions, transaction fees, and other related costs and expenses which shall be incurred by the sponsors or by the sponsors' clients.

None of the supervised persons of the Adviser are currently compensated for the sale of securities, mutual funds, or other investment products.

Item 6 – Performance-Based Fees and Side-By-Side Management

The Adviser does not charge any performance-based fees (fees based on a share of capital gains on or capital appreciation of the assets of a client).

Item 7 – Types of Clients

The Adviser provides portfolio management services to both 1940 Act mutual funds and model portfolios used in wrap fee programs. Requirements for opening and maintaining accounts are determined by the Funds and wrap fee programs.

Item 8 – Methods of Analysis, Investment Strategies and Risk of Loss

The Adviser uses both values-based analysis as well as fundamental, technical and risk analysis in selecting securities for investment. Investing in securities involves risk of loss that clients should be prepared to bear. The Adviser manages its portfolios actively which may involve frequent trading and can negatively affect investment performance through increased transaction costs and taxes.

Masters' Select is used as part of Eventide's investment strategy. With Master's Select, a portfolio manager will review the collective intelligence of proven analysts, portfolio managers, and algorithms as part of the investment decision process. The Adviser believes that utilizing collective intelligence can lead to more consistent performance by addressing the potential gaps in any one individual's investment decisions. But even proven analysts and portfolio managers can incorrectly evaluate the value of a specific security. When the Adviser utilizes Masters' Select, it will only do so as a starting point for its own analysis.

Values based analysis attempts to understand the long term sustainable effects of a company's products, services and practices on its stakeholders based on the belief that companies whose products, services and practices are beneficial to more stakeholders have better long-term outlooks and corresponding better financial returns. However, the Adviser may not be able to correctly ascertain which companies best exhibit these

characteristics and there is no assurance that financial markets will reward these characteristics in a timely fashion. Values based analysis may therefore under-perform other forms of investing. Likewise, since companies that rank poorly based on this type of analysis are generally excluded as potential investments, the investment universe for clients may be smaller than if values based analysis were not applied. This could result in poorer diversification and/or reduced opportunities for returns to clients.

Technical analysis including charting and a variety of calculated metrics attempt to ascertain the most advantageous times or prices for buying, holding or selling securities. The Adviser applies these methods on a per-security basis in concert with other forms of analysis. Technical analysis does not work uniformly well with different securities or in various market climates, leading to the possibility that the analysis can be misapplied. This could result in losses or missed opportunities for gains for clients.

Fundamental analysis attempts to estimate the appropriate valuation of securities based on the current and projected future financial condition of the underlying companies. The Adviser believes that over long time periods financial markets will tend to price the securities nearer to their true underlying value. Hence the Adviser prefers holding securities trading at prices below its estimate of their true value, all else being equal. However, the Adviser may be incorrect in assigning a true underlying value to securities and financial markets can retain prices far away from true values for an extended period of time. In these cases, the use of fundamental analysis may result in the selection of securities which lose value or gain less than other securities.

Risk analysis attempts to balance potential return and risk to the portfolios managed by the Adviser, maximizing return relative to risk. The Adviser evaluates risk in terms of the broad stock market, the US Dollar and in the specific context of each portfolio. The Adviser prefers to accept risks which are less market correlated. As such, the Adviser may take more concentrated positions in individual securities where the Adviser believes that the expected benefit justifies the risk. This can lead to portfolios with relatively low correlation to broad indices, allowing for both out-performance and under-performance versus broad market indices and may cause investors' returns to be more volatile. In its mutual funds, the Adviser sometimes makes use of derivatives and short positions which may individually be quite volatile in order to achieve these goals. The Adviser may use derivatives or other securities to attempt to capture upside of specific events while attempting to limit downside. Use of derivatives generally increases trading and trading costs. The Adviser may not correctly estimate portfolio risk which could cause undesirable portfolio volatility and/or increase losses to clients.

Note that different forms of analysis sometimes indicate very different prospects for a security and the Adviser uses its best judgment to balance these analyses in selecting

securities for portfolios. The Adviser's judgments may not be correct and this could lead to losses or missed opportunities for gains for clients.

If the Adviser trades more frequently as a result of any form of analysis it increases transaction costs to clients and may produce more realized capital gains which could have a negative effect on clients whose assets are not in qualified accounts due to taxes.

Please note that the Adviser recommends the Biotechnology & Pharmaceutical Industry Group to one or more clients as part of their investment strategy. The Adviser may recommend or invest a substantial portion of client assets in biotechnology and pharmaceutical companies if the Adviser believes that the expected benefit to clients justifies the risk, and is consistent with the client's investment objective. Clients should be aware that companies in the Biotechnology & Pharmaceutical Industry Group may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the Biotechnology & Pharmaceutical industry group also may not be financially profitable and thus subject to additional risks.

Item 9 – Disciplinary Information

Registered investment advisers are required to disclose all material facts regarding any legal or disciplinary events that would be material to your evaluation of the Adviser or the integrity of the Adviser's management. The Adviser has no information applicable to this Item.

Item 10 – Other Financial Industry Activities and Affiliations

CIO Finny Kuruvilla is a Principal at Clarus Ventures, a healthcare venture capital firm based in San Francisco and Boston. Dr. Kuruvilla represents Clarus on the board of directors of Nanostring and is a board observer for Catabasis, Lycera, Tetralogic, and Virdante. Dr. Kuruvilla is restricted from trading in the securities of these companies for the Eventide Funds, Eventide Models, as well as his personal accounts. If Dr. Kuruvilla receives material non-public information on a publicly traded company through his responsibilities at Claris Ventures, Dr. Kuruvilla as well as employees of Eventide Asset Management, LLC are restricted from trading in that company for the Adviser's clients as well as personal accounts.

Jason Myhre, the Director of Sales and Marketing for the Adviser, has begun the process of becoming a registered and supervised representative of the broker dealer, Northern Lights

Distributors, LLC. Eventide Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.

Item 11 – Code of Ethics

The Adviser has adopted a Code of Ethics for the purpose of instructing all employees, officers, and directors of the Adviser in their ethical obligations and to provide rules for their personal securities transactions. Below is a summary of our Code of Ethics. We will provide a copy of our Code of Ethics to any client or prospective client upon request.

All employees, officers, and directors of the Adviser owe a fiduciary duty to the Adviser's clients. Policies and procedures have been implemented by the Adviser to ensure that all personal securities transactions be conducted in a such a manner as to avoid any actual or potential conflict of interest or any abuse of any individual's position of trust and responsibility to clients of the Adviser.

All personal securities transactions must also comply with the Adviser's Insider Trading Policy and Procedures.

Employees shall at all times maintain the confidentiality of client identities, security holdings, financial circumstances and other confidential information.

Employees may not execute a securities transaction on a day during which a purchase or sell order in that same security or a related security is pending for a Fund unless the securities transaction is combined ("blocked") with the Fund's transaction or market capitalization of the company is greater than \$500 million. Employees must obtain pre-clearance in writing from the Compliance Department for a personal securities transaction in any security of a company or derivative of a security of a company with a market capitalization of less than \$500 million.

Any securities transactions in a private placement must be authorized by the Adviser's Compliance Officer, in writing, prior to the transaction. In connection with a private placement acquisition, the Compliance Officer must determine whether the investment opportunity should be reserved for a client, and whether the opportunity is being offered to an employee of the Adviser by virtue of the employee's position with the Adviser.

Employees of the Adviser are prohibited from acquiring any securities in an initial public offering without the prior written approval of the Compliance Officer. This restriction is imposed in order to preclude the possibility of an Employee profiting improperly from the Employee's position with the Adviser.

Employees are prohibited from serving on the boards of directors of publicly traded companies, absent prior authorization by the Compliance Officer. In the event that board service is authorized, Employees serving as directors will be isolated from other Employees making investment decisions with respect to the securities of the company in question.

Employees are required to provide a securities holdings report within 10 days of employment with the Adviser, as well as on an annual basis. Employees are also required to provide quarterly transaction reports within 30 days of the end of each calendar quarter. Employees must provide copies of quarterly statements for all broker accounts in which an Employee has bought or sold Reportable Securities or Reportable Funds during the calendar quarter.

The Compliance Officer will, on a quarterly basis, check the trading account statements provided by employees to verify that the Employee has not violated the Code. The Compliance Officer shall identify all Employees, inform those persons of their reporting obligations, and maintain a record of all current and former access persons.

If an employee violates the Code of Ethics, the Compliance Officer will report the violation to the Board of the Fund for appropriate remedial action which, in addition to the actions specifically delineated in other sections of the Code of Ethics, may include a reprimand of the employee, or suspension or termination of the employee's relationship with the Fund and/or the Adviser.

The Adviser does not recommend to clients, or buy or sell for client accounts, securities in which the Adviser or a related person has a material financial interest.

The Adviser allows employees to invest in securities held by a Fund as long as it adheres to the policies outlined in our Code of Ethics. As described above, the Adviser has policies in its Code of Ethics in regards to employees buying or selling securities in personal accounts on the same day that the Adviser is trading the same security in a Fund. The Adviser does not want any employee to profit from a potential price movement resulting from a trade for a Fund. The Adviser does not foresee any other conflict of interest arising from an employee investing in securities held by a Fund.

Item 12 – Brokerage Practices

The Adviser uses multiple brokers to execute trades on behalf of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund. The Adviser's primary objective in directing a trade to a broker is to obtain best execution in terms of share price, quality of service, and commissions paid. The Adviser looks at different factors in selecting brokers and

determining the reasonableness of their commissions. Research and execution are key components. Brokers that provide research generally charge higher commissions for client transactions. So the Adviser weighs the benefit the research provides in investment decision-making against the higher transaction costs for the Funds. The Adviser believes that the use of client commission dollars to obtain research serves the interest of investors and is beneficial for the Gilead Fund and Healthcare & Life Sciences Fund.

Brokers provide proprietary research to the Adviser through access to reports on a broker's website, as well as periodic emails and phone calls to highlight such reports. The bulk of proprietary research is stock specific, but reports also focus on sectors and the macro-economic environment.

When the Adviser uses client brokerage commissions to obtain research, the Adviser obtains a benefit since the Adviser does not need to produce or pay for the research received. This may create an incentive for the Adviser to select a broker-dealer based on its interest in receiving the research, rather than the Funds' interest in receiving most favorable execution. The Adviser's compliance team reviews trades on behalf of the Fund to monitor for best execution.

The Adviser may cause the Funds to pay commissions higher than those charged by other broker-dealers in return for soft dollar benefits. In the last fiscal year, the Adviser received soft dollar benefits as a bundled service from broker-dealers. The Adviser also had a soft dollar arrangement in place with a broker-dealer during the last year. The Adviser received soft dollar credits from client commissions for Gilead Fund trades & Healthcare & Life Sciences Fund trades, which were used for third party research consisting of market and economic data, ethical screening data, and access to subject matter experts. The Adviser may enter into other soft dollar arrangements in the future.

The research the Adviser receives from soft dollar benefits is used to service the Gilead Fund and Healthcare & Life Sciences Fund, but may benefit other advisory clients since clients of the Adviser may have investment objectives that overlap. Since the Adviser's other clients are wrap fee non-discretionary programs, only the Gilead Fund & Healthcare & Life Sciences Fund are paying for soft dollar benefits at this time. The soft dollar benefits received by a Fund may not be proportional to the benefits generated by a Fund. For example, The Gilead Fund may generate more soft dollar benefits than the HLS Fund, but may benefit more or less than the HLS Fund in terms of the research received. The third party research received through soft dollars generally benefits all the Funds. As a result, the Adviser does not seek to allocate soft dollar benefits to a Fund in proportion to the soft dollar credits a Fund generates.

In the last fiscal year, the Adviser received proprietary research and third party research as described above with client brokerage commissions. The Adviser's Portfolio Management

team evaluated the overall value that a broker-dealer's research and execution added to Eventide Funds. The Adviser's Portfolio Management team then sets target trade costs for each broker-dealer based on the value added, and directed trades accordingly. Commissions paid by the Funds on these trades were higher than those charged by brokers for pure execution, but only as permitted by Section 28(e) of the Securities Exchange Act of 1934. The Adviser's CCO reviews the commissions paid to each broker to verify that they are consistent with the assigned targets.

Eventide Asset Management, LLC does not receive client referrals for selecting or recommending broker-dealers. Eventide Asset Management also does not recommend, request or require clients to direct brokerage. Although the Adviser may accommodate a client's desire to direct brokerage in the future, no clients are currently permitted to direct brokerage.

If the same security is traded on a certain day for both Funds, the Adviser will aggregate the trades with a broker-dealer to ensure that both Funds receive the same price (weighted average price).

Item 13 – Review of Accounts

The Adviser's portfolio managers review the investments of the Funds and Models on an ongoing basis for conformity with the investment objectives and policies of the Funds and respective Models. The Adviser's Chief Compliance Officer (CCO) monitors the different Prospectus and SAI restrictions for the Funds on a daily basis through a Compliance Script. The Adviser's CCO also reviews Compliance Reports created by the Funds' Administrator on a monthly basis, and the the Semi-annual and Annual Reports provided to Funds' shareholders on a semi-annual basis. The Adviser is also responsible for providing quarterly disclosures and annual compliance and 15(c) questionnaire responses to the Funds. This allows the Funds to evaluate whether the Adviser is fulfilling its fiduciary obligations. The Adviser's Chief Investment Officer (CIO) and Chief Financial Officer (CFO) reviews the Gilead Fund's and Healthcare & Life Sciences Fund's NAV calculated by the Fund's Accounting Group on a daily basis. The trades and commissions paid by The Funds are also reviewed by the CCO, and CIO on a daily basis.

The sponsors of the wrap fee programs are responsible for providing trade, commission, and performance reporting to their clients.

Item 14 – Client Referrals and Other Compensation

The Adviser does not receive an economic benefit from non-clients. The Adviser also does not compensate anyone for client referrals. The Adviser has, however, entered into a Marketing Services agreement, along with the Funds' Distributor Northern Lights Distributors, LLC, to compensate Multi-funds, LLC for wholesaling services provided for the Funds, from the Adviser's legitimate profits, in circumstances where the Distributor's profits and the Fund's 12b-1 Distribution Plan does not cover such expenses.

Item 15 – Custody

The Adviser does not have custody over client assets.

Item 16 – Investment Discretion

Per the Management Agreement, the Adviser has discretionary authority over the Gilead Fund and HLS Fund. The Adviser will arrange for the placing of all orders for the purchase and sale of portfolio securities for the Funds with broker-dealers selected by the Adviser. The selection of broker-dealers is subject to review by the Board of Trustees, and the Adviser must observe the investment policies, limitations and restrictions of the Funds, which is described in the Funds' prospectus and SAI. The Funds are the only clients for which the Adviser exercises discretion.

Investment guidelines and restrictions must be provided to the Adviser in writing.

Item 17 – Voting Client Securities

Per the management agreement, the Adviser will vote, or make arrangements, to have voted, all proxies on behalf of the Funds. Pursuant to Rule 206(4)-6 and Rule 204-2 under the Advisers Act, the Adviser has adopted and implemented written policies and procedures that are reasonably designed to ensure that the Adviser votes proxies in the best interests of the Funds. The Adviser's Proxy Voting Policies and Procedures are included in the Fund's SAI. The Adviser's Proxy Voting Policies and Procedures covers key objectives including accountability, alignment of management and shareholder interests, and consistency with the Funds' ethical screening criteria. The Policies and Procedures also include the Adviser's voting guidelines for election of the Board of Directors, approval of independent auditors, equity-based compensation plans, as well as corporate structure,

and shareholder rights plans. A copy of the Proxy Voting Policies and Procedures is available, without charge, upon request, by calling 1-877-771-3836. The Adviser will arrange to send a copy of the Proxy Voting Policies and Procedures within three business days of receipt of a request, by first-class mail or other means designed to ensure equally prompt delivery. In addition, the Adviser will provide without charge, upon request, information regarding the proxy votes cast by the Adviser with regard to the Funds' securities.

If proxies are voted by a Third Party proxy voting service provider, the Adviser is responsible for ensuring that the Third Party votes all proxies according to the Adviser's Proxy Policy, and the Adviser is responsible for reviewing such votes on a periodic basis. Generally, clients do not direct proxy voting for particular proxies. In some instances, the Adviser may be asked to cast a proxy vote that presents a conflict between its interests and the interests of the Funds' shareholders. In such a case, the Trust's policy requires that the Adviser abstain from making a voting decision and to forward all necessary proxy voting materials to the Trust to enable the Board of Trustees to make a voting decision. A written record of each proxy received will be kept in the Adviser's files; as well as a record of each vote that is cast; and a copy of any document that was material to making a voting decision.

Item 18 – Financial Information

Registered investment advisers are required in this Item to provide you with certain financial information or disclosures about the Adviser's financial condition. The Adviser has no financial commitment that impairs its ability to meet contractual and fiduciary commitments to clients, and has not been the subject of a bankruptcy proceeding. Under no circumstances do we require or solicit payment of fees in advance of services rendered.

The Adviser's financial statements will be provided upon request.